RESUMEN
Objective: Drug-induced cutaneous reactions are common problem in our country and can range from simple rash to severe reactions. Early recognition of these reactions enables early identification and withdrawal of offending drugs, thereby reducing morbidity and mortality. So present study aimed to assess clinical pattern of drug-induced cutaneous reactions in Dermatology OPD.Methods: This study was an open, non-comparative, non-interventional, observational study conducted on patients visiting dermatology department to see the clinical pattern of drug-induced cutaneous reactions. A total of 60 patients with suspected cutaneous adverse drug reactions were recruited. A detailed physical examination was done by a physician, including drug intake during 3 w preceding reactions and type of drug reactions.Results: Most frequently reported cutaneous drug reactions were Stevens-Johnson Syndrome (23%), Maculopapular rash (18%) Toxic Epidermal Necrolysis (15%) and were caused by antiepileptic drugs in 21(35%) patients, followed by antibiotics in 17(28.33%) cases, NSAID’s in 7(11.6%) cases, antitubercular drugs in 3(5%) and antiretroviral drugs in 3(5%) cases. A high proportioned of these reactions (50%) were moderate (31%) of these were severe because they require hospitalisation or increased the duration of stay in hospital or were life-threatening in (1%). Principal offending drug was phenytoin.Conclusion: A good knowledge of ADRs, a careful history taking and watchful approach while prescribing of drugs can prevent many of adverse drug reactions. These facts justify the development of an intensive programme of pharmacovigilance.
RESUMEN
Objective: The present study aimed to ensure the safety and related potential adverse effects following ChAdOx1 nCoV-19 vaccination (AZD1222) in a scenario when numerous vaccines have been approved on an emergency basis by the WHO and other regulatory agencies to prevent the widespread of COVID-19 infection and to decrease the associated mortality and morbidity.Methods: This study was an open, non-comparative, non-interventional, observational study conducted on healthcare workers of BPS Govt. medical college for women and elderly people who received the first dose of COVID-19 vaccinationChAdOx1 nCoV-19 vaccine (AZD1222) by conducting their interviews and recording the dataResults: Between January and March 2021, a total of 1907 participants were enrolled in this study. Out of 1907 recipients, 70 recipients reports adverse drug events following vaccination. Myalgia (0.629%), headache (1.31%), fever (? 37.5 °C, 0.839%) and fever with chills (? 37.5 °C, 1.048) were the most common adverse events after the first dose of vaccination of ChAdOx1 nCoV-19 vaccine (AZD1222. Throat irritation (0.209 %) and Generalised itching (0.262) were the least common adverse events.Conclusion: ChAdOx1 nCoV-19 (Astrazeneca) has an acceptable safety profile as observed in this study. To our knowledge, very few studies are done that review the safety of COVID-19 vaccines. Further safety data from a larger sample size and of longer duration are warranted to establish safety
RESUMEN
Glaucoma is a group of diseases, characterized by a progressive form of optic nerve damage. Current studies indicate more selective pathophysiological involvement, thereby targeted therapies are warranted. Although both the prostaglandin analogs and beta blockers are still, most commonly used drugs for glaucoma, due to their effi cacy, lack of adverse effects. In addition, a stepped care approach is the corner stone for its management. In addition, attempts have been made to enhance patient compliance and ocular delivery of already available anti-glaucoma drugs such as pilocarpine and timolol maleate. Notable among futuristic treatment options are; novel delivery systems, benzalkonium chloride-free drugs, various glaucoma drainage devices, new targeted therapies and prompt diagnosis plus aggressive treatment, in patients with primary angle closure glaucoma. Promising new focus on vision sparing, greater patient safety and tolerability will provide improved treatment options and long-term preservation of vision and quality of life.